Novartis AG ADR (NVS)vsWarby Parker Inc (WRBY)
NVS
Novartis AG ADR
$148.38
-0.96%
HEALTHCARE · Cap: $273.77B
WRBY
Warby Parker Inc
$22.72
-5.80%
HEALTHCARE · Cap: $3.04B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 6253% more annual revenue ($56.58B vs $890.57M). NVS leads profitability with a 23.9% profit margin vs 0.1%. NVS trades at a lower P/E of 20.6x. NVS earns a higher WallStSmart Score of 49/100 (D+).
NVS
Hold49
out of 100
Grade: D+
WRBY
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-62.1%
Fair Value
$91.39
Current Price
$148.38
$56.99 premium
Margin of Safety
-50.4%
Fair Value
$14.62
Current Price
$22.72
$8.10 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
No standout strengths identified
Areas to Watch
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
ROE of 0.4% — below average capital efficiency
0.1% margin — thin
Operating margin of 0.9%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : WRBY
WRBY has a balanced fundamental profile.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Bear Case : WRBY
The primary concerns for WRBY are Return on Equity, Profit Margin, Operating Margin. A P/E of 2479.0x leaves little room for execution misses. Thin 0.1% margins leave little buffer for downturns.
Key Dynamics to Monitor
NVS profiles as a declining stock while WRBY is a value play — different risk/reward profiles.
WRBY carries more volatility with a beta of 1.96 — expect wider price swings.
WRBY is growing revenue faster at 8.3% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (49/100 vs 31/100), backed by strong 23.9% margins. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Warby Parker Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Warby Parker Inc. (WRBY) is a trendsetting leader in the direct-to-consumer eyewear market, established in 2010 with the mission to revolutionize the way consumers purchase eyewear through a seamless blend of online shopping and an expanding number of retail stores. The company is renowned for its stylish, affordable prescription glasses and sunglasses, appealing to a broad range of customers. Warby Parker's socially conscious business model, epitomized by its "Buy a Pair, Give a Pair" initiative, reflects a commitment to social responsibility by providing eyewear to those in need. With a robust brand reputation and a dedication to innovative marketing strategies, Warby Parker is well-positioned for ongoing growth and success in a competitive landscape.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?